Abstract

Expression of the tumor-associated glycan Tn antigen (αGalNAc-Ser/Thr) has been correlated to poor prognosis and metastasis in multiple cancer types. However, the exact mechanisms exerted by Tn antigen to support tumor growth are still lacking. One emerging hallmark of cancer is evasion of immune destruction. Although tumor cells often exploit the glycosylation machinery to interact with the immune system, the contribution of Tn antigen to an immunosuppressive tumor microenvironment has scarcely been studied. Here, we explored how Tn antigen influences the tumor immune cell composition in a colorectal cancer (CRC) mouse model. CRISPR/Cas9-mediated knock out of the C1galt1c1 gene resulted in elevated Tn antigen levels on the cell surface of the CRC cell line MC38 (MC38-Tnhigh). RNA sequencing and subsequent GO term enrichment analysis of our Tnhigh glycovariant not only revealed differences in MAPK signaling and cell migration, but also in antigen processing and presentation as well as in cytotoxic T cell responses. Indeed, MC38-Tnhigh tumors displayed increased tumor growth in vivo, which was correlated with an altered tumor immune cell infiltration, characterized by reduced levels of cytotoxic CD8+ T cells and enhanced accumulation of myeloid-derived suppressor cells. Interestingly, no systemic differences in T cell subsets were observed. Together, our data demonstrate for the first time that Tn antigen expression in the CRC tumor microenvironment affects the tumor-associated immune cell repertoire.

Highlights

  • Tumor cells are frequently characterized by an aberrant glycosylation profile, current research is focused on how tumor-associated glycan structures support tumor progression

  • Tumorassociated Tn antigen is found in 81–95% of colorectal cancer (CRC) cases, independent of the histological subtype and differentiation status of the tumor, while it is not expressed by the healthy gut mucosa [10, 45, 46]

  • Its expression has been correlated to bad prognosis and increased metastasis [5, 6], the effect of Tn antigen on the anti-tumor immune response has not been investigated in detail

Read more

Summary

Introduction

Tumor cells are frequently characterized by an aberrant glycosylation profile, current research is focused on how tumor-associated glycan structures support tumor progression. Our knowledge on how individual tumor-associated glycan structures affect anti-tumor immunity is still quite limited. Compared to their non-malignant counterparts, tumor cells express much higher levels of the Tn antigen glycan structure [3, 4]. Tn antigen is made up of one N-acetylgalactosamine (GalNAc) monosaccharide and represents the initiation of mucin-type O-glycosylation. Since epithelial cells produce high levels of mucin proteins that are heavily O-glycosylated, high expression of Tn antigen predominantly occurs in epithelial cancer types, including colorectal cancer (CRC), where 86% of primary and metastatic human CRC tissues express the Tn epitope [10]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call